European multicenter trials of curosurf for treatment of neonatal respiratory distress syndrome.
Curosurf, a preparation of polar lipids and hydrophobic proteins isolated from porcine lungs by liquid-gel chromatography, is currently used in European multicenter trials for prevention and treatment of neonatal respiratory distress syndrome (RDS). In babies requiring artificial ventilation with 60-100% oxygen, tracheal instillation of a single dose of Curosurf (200 mg/kg) leads to a dramatic improvement of gas exchange and reduced mortality, without increasing the incidence of neurodevelopmental handicap among survivors. Several factors, including high ventilator pressure and oxygen requirements, have a negative impact on the therapeutic response, suggesting that the patients should be treated at a comparatively early stage of the disease. Clinical trials testing this hypothesis, as well as the effect of multiple treatment doses, are in progress.
Robertson
B
B
Department of Pediatrics, St. Göran's Hospital, Stockholm, Sweden.
D005060:Europe; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015337:Multicenter Studies as Topic; D011663:Pulmonary Surfactants / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D012127:Respiratory Distress Syndrome, Newborn / Q000628:therapy*
D011663:Pulmonary Surfactants